hVIVO Reports Increased Demand for Human Challenge Trials Following New European Contract

hVIVO PLC, the AIM-listed specialist in human challenge trials, has secured a contract with a new European biotechnology client for an influenza challenge study, marking the third such agreement announced in recent months. The development signals what chief executive Yamin Khan characterised as a marked improvement in market conditions following a subdued 2025.

The trial is scheduled to commence imminently, with the majority of revenue anticipated to be recognised during 2026 and the remainder extending into 2027. Khan indicated that the contract represents evidence of a “significant uptick” in both pipeline opportunities and conversion rates, supported by enhanced sales capabilities within the organisation.

The chief executive emphasised a strategic shift in the company’s approach to contract announcements. hVIVO now discloses only fully executed clinical trial agreements rather than preliminary startup agreements. This policy change reduces cancellation risk and accelerates the timeline for revenue recognition, providing greater certainty for the business.

Addressing the broader commercial environment, Khan acknowledged that 2025 presented challenges for the sector. However, the company utilised this period to establish four distinct business pillars encompassing consulting services, clinical trials, laboratory services, and human challenge trials. This diversification strategy aims to deliver comprehensive capabilities across multiple therapeutic areas beyond the company’s traditional infectious disease focus.

Whilst pursuing diversification, hVIVO has continued to expand its core human challenge trial expertise. The company has developed new challenge models for human metapneumovirus and updated its influenza models. The newly announced European contract will employ one of these recently developed influenza challenge models, demonstrating practical application of the enhanced capabilities.

From a financial perspective, Khan disclosed that hVIVO entered 2026 with an order book valued at approximately £30 million, of which £25 million was expected to be recognised during the current year. The recent contract wins, including three human challenge trials and several smaller agreements, have strengthened revenue visibility for 2026 and begun to establish foundations for 2027 performance.

The company maintains its guidance for high single-digit revenue growth between 2025 and 2026. Management expressed confidence in achieving this target, supported by the improved conversion of pipeline opportunities into contracted revenue. Khan stated that the business remains on track to deliver the projected growth whilst simultaneously building a more predictable revenue base for the following year.

The succession of contract announcements follows a period of market weakness in 2025, suggesting a potential recovery in demand for specialised clinical trial services. hVIVO’s position as a specialist provider of human challenge trials positions the company to benefit from renewed investment in infectious disease research and vaccine development programmes.

The strategic emphasis on announcing only fully contracted clinical trials, rather than earlier-stage agreements, reflects a more conservative approach to revenue forecasting. This methodology should provide investors with greater confidence in the quality and certainty of the company’s reported order book and forward revenue projections.